BIO Asia International Conference Company Presentation
Date:
Monday, March 19
Time:
11:45am (Tokyo Time – GMT+9)
Location:
Grand Hyatt Tokyo
Wall Street Investor Forum Company Presentation
Date:
Thursday, March 22
Time:
08.00am Eastern Time
Location:
University Club of NYC
Webcast:
https://goo.gl/7h3CCo
About BIO Asia International Conference The 15th Annual BIO Asia International Conference, co-hosted by the Biotechnology Innovation Organization (BIO), BioCentury and the Japan Bioindustry Association (JBA), brings together the global biotechnology and pharmaceutical industry to explore licensing and research collaborations in the current Asia-Pacific business and policy environments. Attendees can gain insights into the changes, challenges, and opportunities key opinion and policy leaders foresee for the Japanese biotech market. The conference will take place March 19-20, 2018 at the Grand Hyatt. Tokyo. For more information: https://goo.gl/ZPYT8k.
About Wall Street Investor Forum Wall Street Investor Forum has conducted 85 multitrack analyst conferences in which over 1800 different NYSE/NASDAQ/OTC companies have presented and over 3000 different institutions have attended in New York, Boston & London since 1990. Although the conferences is now focused on micro/small cap companies, public companies ranging from General Electric, Microsoft Corp, Mattel, Inc., Pfizer, Inc., Biogen, Unilever, EMC, and America Online have presented. Institutions ranging from Gabelli & Company, Neuberger Berman, Wellington Management, JP Morgan Asset Management, Dreyfus, Putnam Management have attended. For more information: https://goo.gl/JgE5u2.
About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U.S., a clinically meaningful benefit was demonstrated by a higher response to NurOwn compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.
CONTACTS Corporate: Uri Yablonka Chief Business Officer BrainStorm Cell Therapeutics Inc. Phone: 646-666-3188 uri@brainstorm-cell.com
Contacts
Corporate:
Uri Yablonka
Chief Business Officer
BrainStorm Cell Therapeutics Inc.
Phone: 646-666-3188
uri@brainstorm-cell.com
Investors:
Michael Rice
LifeSci Advisors LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com
Media:
Matt Middleman, M.D.
LifeSci Public Relations, LLC
Phone: 646-627-8384
matt@lifescipublicrelations.com